If you’re here, you already know what time it is. Mind  your manners coming through the door and hit that Like button. It costs you less than a second to do it. I want to chop it up with you about a stock that I’m invested in that has been making quiet moves albeit very significant moves. You won’t find too much chatter about it surprisingly when you look at its growth over the past 12 months and its projected path. There are plenty of Bio tech stocks out there but this one is solid and continues to be so week to week month to month. That stock is Sesen Bio inc.

Support: https://linktr.ee/moneytalksundayz

Sesen Bio, or ticker symbol SESN, is up a whopping 417.72% over the last 12 months. It is currently trading at $4.13. I originally bought in at $2.96 back on May 26th of this year. In around a month and a half it’s approaching double its price. This is one of my long plays and quietly one of my favorites based upon it’s performance. The only downside in my opinion about this stock is that it doesn’t pay dividends so when my long play is over I will be dumping the stock and walking away with my profit. That is unless they switch it up and decide to pay dividends.

Across the market though, SESN is rated a strong buy. InvestorsObserver’s proprietary ranking system, gives SESN stock a score of 83 out of a possible 100. That rank is influenced by a long-term technical score of 98. SESN's rank also includes a fundamental score of 80.

Wall Street Zen as well as Tip Ranks also rate the stock a buy and are bullish about it. The general consensus is the same as far as the price target goes. All sources are in agreement at or around the $7-7.50 range. It is forecasted to hit that price mark in about 10-12 months. That gives you plenty of time to load up on shares and set your alerts for when it nears the price target to get ready to move out. But you will have to move fast.

So what is SESN and how is it doing in the news?

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in phase 3 clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate for use in the treatment of various types of EpCAM-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Today, Sesen Bio Inc (SESN) stock has risen 5.83% while the S&P 500 is up 0.65% as of 1:41 PM on Wednesday, Jul 21. SESN is up $0.23 from the previous closing price of $3.86 on volume of 3,254,475 shares. Over the past year the S&P 500 has risen 33.58% while SESN is up 417.72%. SESN's revenue has grown faster (73.99% per year) than the US market average (17.35%).

Institutions currently hold roughly 23% of the stock, 10% to insiders, and the rest to retail investors. Of the institutional investing, Vanguard Group Inc holds the most with 7,195,552 shares valued at $28.28 million.

Talk about M’s baby.